Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 175

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Identification of Subtypes in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome

Open access
Staaf, Johan, Ringnér, Markus, Vallon-Christersson, Johan, Jönsson, Göran, Bendahl, Pär-Ola, Holm, Karolina, Arason, Adalgeir, Gunnarsson, Haukur, Hegardt, Cecilia, Agnarsson, Bjarni A., Luts, Lena, Grabau, Dorthe, Fernö, Mårten, Malmström, Per-Olof, Johannsson, Oskar Th., Loman, Niklas, Barkardottir, Rosa B., Borg, Åke·2010·Journal of Clinical Oncology

Abstract

Purpose: Human epidermal growth factor receptor 2 (HER2) gene amplification or protein overexpression (HER2 positivity) defines a clinically challenging subgroup of patients with breast cancer (BC) with variable prognosis and response to therapy. We aimed to investigate the heterogeneous biologic appearance and clinical behavior of HER2-positive tumors using molecular profiling. Patients and Methods: Hierarchical clustering of gene expression data from 58 HER2-amplified tumors of various stage, histologic grade, and estrogen receptor (ER) status was used to construct a HER2-derived prognostic predictor that was further evaluated in several large independent BC data sets. Results: Unsupervised analysis identified three subtypes of HER2-positive tumors with mixed stage, histologic grade, and ER status. One subtype had a significantly worse clinical outcome. A prognostic predictor was created based on differentially expressed genes between the subtype with worse outcome and the other subtypes. The predictor was able to define patient groups with better and worse outcome in HER2-positive BC across multiple independent BC data sets and identify a sizable HER2-positive group with long disease-free survival and low mortality. Significant correlation to prognosis was also observed in basal-like, ER-negative, lymph node–positive, and high-grade tumors, irrespective of HER2 status. The predictor included genes associated with immune response, tumor invasion, and metastasis. Conclusion: The HER2-derived prognostic predictor provides further insight into the heterogeneous biology of HER2-positive tumors and may become useful for improved selection of patients who need additional treatment with new drugs targeting the HER2 pathway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2009.22.8775

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 175

Metadata

Authors
Staaf, J., Ringnér, M., Vallon-Christersson, J., Jönsson, G., Bendahl, P.-O., Holm, K., Arason, A., Gunnarsson, H., Hegardt, C., Agnarsson, B. A., Luts, L., Grabau, D., Fernö, M., Malmström, P.-O., Johannsson, O. T., Loman, N., Barkardottir, R. B., & Borg, Å.
Venue
Journal of Clinical Oncology
Published
2010-04-10
Volume
28
Issue
11
Pages
1813-1820
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2106714771
Cited by
175
References
8
FWCI
10.11
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of Subtypes in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome. https://app.cochat.ai/papers/10.1200/jco.2009.22.8775
The paper
Staaf, J., Ringnér, M., Vallon-Christersson, J., Jönsson, G., Bendahl, P.-O., Holm, K., Arason, A., Gunnarsson, H., Hegardt, C., Agnarsson, B. A., Luts, L., Grabau, D., Fernö, M., Malmström, P.-O., Johannsson, O. T., Loman, N., Barkardottir, R. B., & Borg, Å. (2010). Identification of Subtypes in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.22.8775

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.